High expression of ALYREF correlates with poor prognosis in patients, as evidenced in hepatocellular carcinoma (HCC), glioblastoma, glioma, neuroblastoma, lung adenocarcinoma, bladder cancer, and breast cancer [92]. Here, ALYREF is linked to breast carcinoma.